Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Down 5.8% – Here’s What Happened

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) shares fell 5.8% during mid-day trading on Wednesday . The stock traded as low as $12.8955 and last traded at $12.9945. 323 shares were traded during trading, a decline of 97% from the average daily volume of 11,785 shares. The stock had previously closed at $13.80.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Santen Pharmaceutical Trading Down 0.7%

The company has a 50-day moving average price of $12.32 and a two-hundred day moving average price of $11.45. The stock has a market cap of $4.15 billion and a P/E ratio of 0.10.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.